Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

PAVmed (PAVM) EBITDA Margin (2021 - 2025)

PAVmed has reported EBITDA Margin over the past 5 years, most recently at 8398.77% for Q4 2025.

  • Quarterly results put EBITDA Margin at 8398.77% for Q4 2025, up 4347123.0% from a year ago — trailing twelve months through Dec 2025 was 21808.0% (down 1934227.0% YoY), and the annual figure for FY2025 was 21806.0%, down 2032062.0%.
  • EBITDA Margin for Q4 2025 was 8398.77% at PAVmed, up from 96880.0% in the prior quarter.
  • Over the last five years, EBITDA Margin for PAVM hit a ceiling of 201925.0% in Q1 2021 and a floor of 96880.0% in Q3 2025.
  • Median EBITDA Margin over the past 5 years was 8398.77% (2025), compared with a mean of 11717.21%.
  • Biggest five-year swings in EBITDA Margin: tumbled -21231389bps in 2022 and later surged 4347123bps in 2025.
  • PAVmed's EBITDA Margin stood at 6559.67% in 2021, then crashed by -235bps to 21965.18% in 2022, then soared by 93bps to 1561.77% in 2023, then tumbled by -3221bps to 51870.0% in 2024, then surged by 84bps to 8398.77% in 2025.
  • The last three reported values for EBITDA Margin were 8398.77% (Q4 2025), 96880.0% (Q3 2025), and 78583.33% (Q2 2025) per Business Quant data.